AIM IMMUNOTECH INC
AIMNYSE AMERICANTrading Snapshot
- Day Range
- $0.18 – $0.19
- 52-Week Range
- $0.18 – $2.79
- Volume
- $1.95B
- Avg Volume
- $1.57B
- Shares Outstanding
- 3.4M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $88,000
- Last Q Revenue
- $26,000
- P/E Ratio
- -0.0
- P/S Ratio
- 6.6x
- EPS (TTM)
- $-0.83
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +96.1%
Why Investors Own AIM
- ✓High-growth profile — revenue up +13.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AIM IMMUNOTECH INC
AIM
StockOtter · stockotter.spaceAbout AIM IMMUNOTECH INC
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition
1947 Oil & Gas, a newly listed oil and gas producer focused on US assets, began trading on London's AIM market on Monday with an initial valuation of about £65 million. The company issued 500 million shares at 10p each,
1947 Oil & Gas makes AIM debut with ambitions to grow production sharply in coming years
1947 Oil & Gas PLC (AIM:1947) begins trading on AIM today, with shares marked at a premium price and ambitions to lift production from its newly acquired US Gulf of America assets by around 50% over the next two years. I
Digitalbox eyes creator-led growth as it rides out Meta disruption
Digitalbox PLC (AIM:DBOX, FRA:RLXB), the mobile-first digital media group behind The Daily Mash and The Tab, believes the upheaval sweeping digital media presents significant opportunities for nimble players, and says a
AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib
Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in
Shore Capital cheers Coiled Therapeutics dosing progress
Shore Capital has welcomed the latest step forward in Coiled Therapeutics' (AIM:COIL, OTCQB:COTXF) cancer drug trial, reiterating its support for the AIM-listed group. The broker was responding to Monday's news that Coil
Coiled Therapeutics fills two cohorts as reworked cancer drug advances
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has enrolled the first patients into two dose groups testing a reformulated version of its experimental cancer drug. The AIM-listed oncology group said it had signed up three p